logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5115.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5115.produseast1
World Hepatitis Day 2023 | Collections | MSF Science Portal
World Hepatitis Day 2023

World Hepatitis Day 2023

Viral hepatitis is a major cause of disease and death globally. To mark World Hepatitis Day (July 28th) we present a selection of recent MSF research exploring how to effectively deploy powerful medical tools that could turn the tide on hepatitis C and E—but now reach only a tiny fraction of people who desperately need them, especially in low-resource and emergency settings.

For hepatitis C, where groundbreaking new antiviral drugs can cure nearly all patients, MSF is piloting simplified, community-based models of care that offer rapid screening, diagnosis, and treatment under one roof. Some programs focus on the complex needs of highly vulnerable, hard-to-reach populations, such as people co-infected with HIV or TB or who inject drugs.

Turning to prevention, an ongoing vaccination campaign against hepatitis E in an outbreak setting is showing early signs of short-term protection. Final results from this South Sudanese refugee camp, where poor sanitation and water quality regularly lead to outbreaks, should help plug a key evidence gap that—along with other barriers discussed in a commentary article—impedes widespread uptake of the vaccine.

Collection Content

Conference Material
|
Abstract

Safety of hepatitis E vaccination in pregnancy following the first mass reactive vaccination campaign in Bentiu, South Sudan

Nesbitt RC
2023-06-08 • Epicentre Scientific Day Paris 2023
2023-06-08 • Epicentre Scientific Day Paris 2023
BACKGROUND
Hepatitis E causes high mortality among pregnant women with case fatality risks of 10-25%, and adverse fetal outcomes. Hecolin® is a safe and efficacious vaccine against H...
Conference Material
|
Slide Presentation

Two-dose vaccine effectiveness following the first reactive mass vaccination campaign against Hepatitis E in Bentiu, South Sudan

Nesbitt RC, Rumunu J, Asilaza VK, Gitahi P, Nkemenang P,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
Journal Article
|
Research

Nurse-led initiation of hepatitis C care in rural Cambodia

O’Keefe D, Samley K, Bunreth V, Marquardt T, Bobi SE,  et al.
2023-04-01 • Bulletin of the World Health Organization
2023-04-01 • Bulletin of the World Health Organization
OBJECTIVE
To determine whether a nurse-led model of care for patients with hepatitis C virus (HCV) infections can provide safe and effective diagnosis and treatment in a resource-poo...
Journal Article
|
Research

Hepatitis C treatment program in Maputo, Mozambique, the challenge of genotypes and key populations: A 5-year retrospective analysis of routine programmatic data

Loarec A, Gutierrez AG, Muvale G, Couto AM, Nguyen AP,  et al.
2023-03-30 • Health Science Reports
2023-03-30 • Health Science Reports
BACKGROUND AND AIMS
Hepatitis C (HCV) programs face challenges, especially linked to key populations to achieve World Health Organization (WHO) goals of eliminating hepatitis. Médeci...
Journal Article
|
Research

A simplified point-of-service model for hepatitis C in people who inject drugs in South Africa

Saayman E, Hechter V, Kayuni N, Sonderup MW
2023-03-04 • Harm Reduction Journal
2023-03-04 • Harm Reduction Journal

BACKGROUND

Globally, 9% of people who inject drugs (PWID), a key hepatitis C-infected population, reside in sub-Saharan Africa. In South Africa, hepatitis C seroprevalence in PW...

Journal Article
|
Research

Epidemiological characteristics and real-world treatment outcomes of hepatitis C among HIV/HCV co-infected patients in Myanmar: A prospective cohort study

Swe TM, Johnson DC, Mar HT, Thit P, Homan T,  et al.
2023-02-17 • Health Science Reports
2023-02-17 • Health Science Reports
BACKGROUND AND AIMS
In Myanmar, public sector treatment programs for hepatitis C virus (HCV) infection were nonexistent until June 2017. WHO highlights the importance of simplificati...
Journal Article
|
Commentary

Hepatitis E vaccine—Illuminating the barriers to use

Lynch JA, Lim JK, Asaga PEP, Wartel TA, Marti M,  et al.
2023-01-05 • PLOS Neglected Tropical Diseases
2023-01-05 • PLOS Neglected Tropical Diseases
Journal Article
|
Research

Integrating hepatitis C treatment into multidrug-resistant TB care

Kirakosyan O, Melikyan N, Falcao J, Khachatryan N, Atshemyan H,  et al.
2022-06-21 • Public Health Action
2022-06-21 • Public Health Action
BACKGROUND
Direct-acting antivirals (DAAs) are not widely used for patients with chronic hepatitis C virus (HCV) infection and multidrug- or rifampicin-resistant TB (MDR/RR-TB). We d...

See more collections

Reshaping TB care in low-resource settings (MSF Scientific Days International 2022)

Reshaping TB care in low-resource settings (MSF Scientific Days International 2022)
No description available
MSF logo

Prevalence and outcomes of antibiotic resistant infections at MSF projects
No description available
World Malaria Day 2023

World Malaria Day 2023
World Malaria Day is April 25th. The theme for 2023 is "Zero malaria: invest, innovate, implement" and the importance of reaching marginalized populations with the tools and strategies that are currently available. This collection highlights research on this theme, especially the latter two "i's": From research on Seasonal Chemoprophylaxis (SMC) and mass drug administration (MDA), to analyzing the reach of gene mutations (HRP2) in new environments, to other interventional research topics, these articles show how innovative approaches can be successfully implemented even in the most challenging settings to fight this global public health threat.
View All Collections